|1.||Amino, Mari: 8 articles (12/2015 - 03/2003)|
|2.||Yoshioka, Koichiro: 6 articles (12/2015 - 03/2003)|
|3.||Inokuchi, Sadaki: 5 articles (12/2015 - 03/2003)|
|4.||Kodama, Itsuo: 5 articles (04/2010 - 01/2006)|
|5.||Tanabe, Teruhisa: 5 articles (04/2010 - 03/2003)|
|6.||Ikari, Yuji: 4 articles (12/2015 - 01/2006)|
|7.||Nakagawa, Yoshihide: 4 articles (12/2015 - 03/2003)|
|8.||Sugiyama, Atsushi: 4 articles (01/2014 - 06/2003)|
|9.||Morita, Seiji: 4 articles (04/2010 - 03/2003)|
|10.||Takano, Teruo: 4 articles (01/2010 - 07/2005)|
08/01/2003 - "Nifekalant hydrochloride (MS-551), a pure K(+) channel blocker, might be effective for postoperative recurrent ventricular tachyarrhythmias that are refractory to other antiarrhythmic agents."
12/13/2002 - "Nifekalant is a class III antiarrhythmic drug that has been shown to be effective against ventricular tachyarrhythmias in experimental animals and humans. "
02/01/1992 - "These results suggest that MS-551 is a pure class III antiarrhythmic drug which may be effective in the treatment of life-threatening reentrant tachyarrhythmias, but not in automaticity arrhythmias."
12/13/2002 - "Thus, nifekalant inhibits HERG channels in a voltage-dependent and frequency-dependent manner, and the inhibitory effect may underlie the clinical efficacy of the drug against ventricular tachyarrhythmias."
05/01/1998 - "The effects of intravenous MS-551, a new class III antiarrhythmic drug, on atrium and ventricle were evaluated in 6 patients with ventricular tachyarrhythmias (4 males and 2 females; mean age 45 +/- 21 years) in an electrophysiologic study. "
06/01/2007 - "[Nifekalant hydrochloride effective against perioperative ventricular tachycardia in patients with impaired left ventricular function]."
01/01/2007 - "Nifekalant (NF) is a novel class III antiarrhythmic agent that is effective in preventing life-threatening ventricular tachycardia/fibrillation (VT/VF). "
04/01/2013 - "We also found that in these sheets, nifekalant showed a clear dose-dependent increase in the size of the unexcitable 'cores' of these induced spiral waves, an important parallel with the treatment for ventricular tachycardia in the clinical situation, which was not shown properly in cardiac-cell sheets derived from dissociated rodent hearts. "
08/05/2010 - "Nifekalant hydrochloride terminating sustained ventricular tachycardia accompanied with QT dispersion prolongation."
10/01/2007 - "Nifekalant is a class III antiarrhythmic drug, which is usually used for suppression of ventricular tachycardia (VT) and fibrillation. "
03/01/2004 - "Nifekalant hydrochloride is a class III antiarrhythmic drug that has been found to be effective against VT and ventricular fibrillation. "
01/01/2005 - "Defibrillation effects of intravenous nifekalant in patients with out-of-hospital ventricular fibrillation."
02/01/1995 - "The data indicate that a multiple-dose regimen of MS-551 provides protection against ischemia-induced ventricular fibrillation (VF) in the postinfarcted heart. "
04/01/2006 - "Although nifekalant is a class III antiarrhythmic agent without negative inotropic activity, its effect in patients with shock-refractory ventricular fibrillation remains unclear. "
02/01/1995 - "MS-551 protects against ventricular fibrillation in a chronic canine model of sudden cardiac death."
|4.||Heart Arrest (Cardiac Arrest)
11/01/2010 - "Nifekalant hydrochloride for patients with cardiac arrest caused by shockable rhythm."
01/01/2006 - "Can nifekalant hydrochloride be used as a first-line drug for cardiopulmonary arrest (CPA)? "
09/01/2006 - "Nifekalant hydrochloride administration during cardiopulmonary resuscitation improves the transmural dispersion of myocardial repolarization: experimental study in a canine model of cardiopulmonary arrest."
09/01/2006 - "Because nifekalant hydrochloride (NIF) displayed a superior defibrillating effect on ventricular tachycardia/fibrillation (VT/VF) in cardiopulmonary arrest (CPA) patients, despite some QT prolongation, its effect on transmural dispersion of repolarization (TDR) in the left ventricle (LV) in an animal model of CPA was investigated. "
08/01/2010 - "To compare the efficacy of nifekalant and amiodarone in the treatment of cardiac arrest in a porcine model. "
02/01/1998 - "As MS-551 is being used as a trial on medically followed patients, it was unknown how effective clinically on the acute myocardial infarction. "
04/01/1994 - "We examined the effects of MS-551 (1,3-dimethyl-6-[(2-[N-(2-hydroxyethyl)-3-(4- nitrophenyl)propylamino]ethylamino] 2,4(1H,3H)-pyrimidinedione hydrochloride), a new class III antiarrhythmic drug, on programmed electrical stimulation (PES)-induced ventricular arrhythmias, the effective refractory period (ERP), intraventricular conduction, and hemodynamics in a canine myocardial infarction (MI) model. "
04/01/1994 - "Effects of MS-551, a new class III antiarrhythmic drug, on programmed stimulation-induced ventricular arrhythmias, electrophysiology, and hemodynamics in a canine myocardial infarction model."
11/01/2002 - "Anti-arrhythmic efficacy of nifekalant hydrochloride, a pure class III anti-arrhythmic agent, in patients with healed myocardial infarction and inducible sustained ventricular tachycardia."
07/01/2001 - "Efficacy of nifekalant hydrochloride on the treatment of life-threatening ventricular tachyarrhythmias during reperfusion for acute myocardial infarction."
|4.||Sotalol (Sotalol Hydrochloride)
|10.||Potassium Channels (Potassium Channel)
|2.||Cardiopulmonary Resuscitation (CPR)
|3.||Electric Countershock (Cardioversion)